This invention provides compositions that include a protein and at least two protease inhibitors, method for treating diabetes mellitus, and methods for administering same, and methods for oral administration of a protein with an enzymatic activity, including orally administering same.

The present application discloses a membrane-type metalloprotease inhibitory protein T1.sup.PrαTACE and use thereof, which can be used for preparing drugs targeting MT1-MMP or TACE endonuclease. The present application discloses an antitumor pharmaceutical composition, comprising BHK-21 cells and an artificial basal membrane which expresses T1.sup.PrαTACE protein.

The present application discloses a membrane-type metalloprotease inhibitory protein T1.sup.PrαTACE and use thereof, which can be used for preparing drugs targeting MT1-MMP or TACE endonuclease. The present application discloses an antitumor pharmaceutical composition, comprising BHK-21 cells and an artificial basal membrane which expresses T1.sup.PrαTACE protein.

Provided herein are compositions and methods of using base editors comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain in conjunction with a guide polynucleotide. Also provided herein are base editor systems for editing nucleobases of target nucleotide sequences.

Provided herein are compositions and methods of using base editors comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain in conjunction with a guide polynucleotide. Also provided herein are base editor systems for editing nucleobases of target nucleotide sequences.

Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)

Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)

A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells a thrombin inhibitor.

A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells a thrombin inhibitor.

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.